Deqtynet (copper (64Cu) oxodotreotide)

Where it stands

Deqtynet (copper (64Cu) oxodotreotide), from CIS bio international, has been refused an EU marketing authorisation. The records show the CHMP adopted a negative opinion on 21 May 2026, and the EU refusal is recorded on 3 August 2026. No approval date exists.

The proposed indication was positron emission tomography (PET) for localising somatostatin receptor-positive neuroendocrine neoplasms (NENs). The therapeutic area is listed as radionuclide imaging, so this is a diagnostic radiopharmaceutical, not a treatment.

The records do not give the reasons for the negative opinion, so no conclusion about the data package or the CHMP's concerns can be drawn from them.

Regulatory pathway and designations

The product carries an Orphan designation, and the records place it in the EU centralised procedure, where the CHMP gives a scientific opinion and the European Commission then issues a legally binding decision. Here the CHMP opinion was negative, and the Commission's refusal decision followed about ten weeks later, on 3 August 2026.

In general, an applicant can ask for re-examination of a negative CHMP opinion within a short window after receiving it, and must then submit detailed grounds. The records do not say whether CIS bio international requested re-examination. They show only the opinion and the final refusal.

Orphan designation does not guarantee approval; the product still has to meet the standard benefit-risk and quality requirements. Without an authorisation, the benefits tied to an authorised orphan medicine, such as market exclusivity, do not arise. The records say nothing on the current status of the designation.

Safety and pharmacovigilance

The records contain no safety data, no information on adverse events, and no risk management or post-authorisation commitments. They also do not say whether safety, efficacy, quality or another issue drove the negative opinion.

Because the product was refused, no EU post-marketing pharmacovigilance obligations apply to it. Readers who need the CHMP's reasoning should consult the EMA's published assessment documentation for the refusal, which was not provided here.

What to watch

First, watch for the EMA's published assessment report and question-and-answer document on the refusal. These typically set out the grounds and would show whether the concerns were clinical, methodological or quality-related.

Second, watch for any company statement on next steps, such as a new application, additional data generation or a different regulatory route. The records contain no such statement, and none should be assumed.

Third, because the product is a PET agent for somatostatin receptor-positive NENs, other authorised imaging options for that setting are relevant context for stakeholders. The records do not describe them, so any comparison needs outside sources.